Felix Guerrero-Ramos, MD

Articles by Felix Guerrero-Ramos, MD

TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC

ByFelix Guerrero-Ramos, MD,Aislinn Antrim, Managing Editor

October 18th 2025

Felix Guerrero-Ramos, MD, outlines molecular and pharmacologic findings from SunRISe-1, including the high prevalence of TP53 alterations and the extended drug exposure achieved with the TAR-200 intravesical delivery system.

Latest Updated Articles

Felix Guerrero-Ramos, MD

Articles by Felix Guerrero-Ramos, MD

TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC

Latest Updated Articles

Trending on Pharmacy Times

Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer

Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer

Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer

Under Pressure: A Brief Overview of the Updated Hypertension Guidelines

TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC